Effects of unsymmetrical ester substituted 1,4-dihydropyridine derivatives and their optical isomers on contraction of smooth muscle

  • R. Towart
  • E. Wehinger
  • H. Meyer
Short Communications

Summary

The optical isomers of two nifedipine-like 1,4-dihydropyridine derivates have been synthesised and tested in vitro. The (−)-isomer (S-configuration of both compounds) was more potent than the racemate, which in turn was more potent than the (+)-isomer (R-configuration). The S-configuration isomers are approximately ten times more potent than nifedipine, and may represent the optimal structure and configuration for binding to and inhibiting calcium channels.

Key words

1,4-Dihydropyridines Optical isomers Stereospecificity Nifedipine Calcium antagonists 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bayer R, Kalusche D, Kaufmann R, Mannhold R (1975) Inotropic and electrophysiological actions of verapamil and D600 in mammalian myocardium. III Effects of the optical isomers on transmembrane action potentials. Naunyn-Schmiedeberg's Arch Pharmacol 290:81–97Google Scholar
  2. Bolton TB (1979) Mechanism of action of transmitters and other substances on smooth muscle. Physiol Rev 59:606–718Google Scholar
  3. Bossert F, Horstmann H, Meyer H, Vater W (1979) Einfluß der Esterfunktion auf die vasodilatierenden Eigenschaften von 1,4-Dihydro-2,6-dimethyl-4-nitrophenyl-pyridin-3,5-dicarbonsäureestern. Arzneim Forsch (Drug Res) 29:226–229Google Scholar
  4. Daniel EE (1963) On roles of calcium, strontium and barium in contraction and excitability of rat uterine muscle. Arch Int Pharmacodyn 146:298–349Google Scholar
  5. Diem K, Lentner C (1970) (eds) Statistical methods. In: Documenta Geigy, Basel, pp 174–183Google Scholar
  6. Fleckenstein A (1977) Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Ann Rev Pharmacol Toxicol 17:149–166Google Scholar
  7. Furchgott RF, Bhadrakom S (1953) Reactions of strips of rabbit aorta to epinephrine, isopropylarterenol, sodium nitrite and other drugs. J Pharmacol Exp Ther 108:129–143Google Scholar
  8. Gunther H (1973) NNR-Spektoskopie. G. Thieme Verlag, Stuttgart, p 332Google Scholar
  9. Massingham R (1973) A Study of compounds which inhibit vascular smooth muscle contraction. Eur J Pharmacol 22:75–82Google Scholar
  10. Meyer H, Bossert F, Wehinger E, Stoepel K, Vater W (1981) Synthese and vergleichende pharmakologische Untersuchungen von 1,4-Dihydro-2,6-dimethyl-1-4-(3-nitrophenyl)pyridin-3,5-dicarbonsäureestern mit nicht-identischen Esterfunktionen. Arzneim Forsch (Drug Res) 31:407–409Google Scholar
  11. Rodenkirchen R, Bayer R, Steiner R, Bossert F, Meyer H, Möller E (1979) Structure activity studies on nifedipine in isolated cardiac muscle. Naunyn-Schmiedeberg's Arch Pharmacol 310:69–78Google Scholar
  12. Rosenberger L, Triggle DJ (1978) Calcium, calcium translocation, and specific calcium antagonists. In: Weiss GB (ed) Calcium in Drug Action. Plenum Press, New York, pp 3–31Google Scholar
  13. Sato M, Nagao T, Yamaguchi I, Nakajima H, Kiyomoto A (1971) Pharmacological studies on a new 1,5-benzothiazepine derivative (CRD-401). Arzneim Forsch (Drug Res) 21:1338–1343Google Scholar
  14. Shibanuma T, Iwanani M, Okuda K, Takenaka T, Murakami M (1980) Synthesis of optically active 2-(N-benyl-N-methylamino)-ethyl methyl 2,6-dimethyl-4-(M-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (nicardipine). Chem Pharm Bull 28:2809–2812Google Scholar
  15. Vater W, Kroneberg G, Hoffmeister F, Kaller H, Meng K, Oberdorf A, Puls W, Schloßmann K, Stoepel K (1972) Zur Pharmakologie von 4-(2-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbosäuredimethylester (nifedipine, BAY a 1040). Arzneim Forsch (Drug Res) 22:1–14Google Scholar
  16. Wehinger E, Meyer H, Bossert F, Vater W, Towart R, Stoepel K, Kazda S (1979), Bayer AG, German Offenlegungsschrift 2935451 (filed Setember 1st, 1979).Google Scholar

Copyright information

© Springer-Verlag 1981

Authors and Affiliations

  • R. Towart
    • 1
  • E. Wehinger
    • 2
  • H. Meyer
    • 2
  1. 1.Institut für PharmakologieWuppertal 1Germany
  2. 2.Chemisch-Wissenschaftliches Laboratorium Pharma Bayer AGWuppertal 1Germany

Personalised recommendations